48 results about "Topical agents" patented technology

A fibrillin production promoter contains at least one pyrimidine nucleotide or precursor thereof as an active ingredient.

The invention relates to the substances benfo-oxythiamine and / or oxythiamine for use as the active ingredient of a topically administered medicament for the therapeutic treatment of patients with a disease of the body surface skin (cutis and subcutis) and / or one or more mucous membranes (mucosa) caused by viruses. The medicament is administered at a time when viral replication has already taken place and viral release from the host cell(s) is imminent.Benfo-oxythiamine and / or oxythiamine cause (I) a slowing or prevention of the spread mechanisms of the viruses, so that the viruses remain in their host cells after replication and cell damage in the patient organism (host organism) is reduced or prevented, and (II) an immune response against the viruses remaining in the cells, so that the patient's immune system is activated or reactivated to generate an effective immune response against the viruses.

The invention relates to (i) the prevention or treatment of a sleep disturbance, preferably in a patient having neuropathic pain; and / or (ii) the prevention or treatment of neuropathic pain in a patient having a sleep disturbance; and / or (iii) the prevention or treatment of neuropathic pain in a patient having been treated previously and / or being treated concomitantly with an analgesic medication for relief of neuropathic pain, preferably selected from antiepileptics, antidepressants and opioid analgesics, wherein the patient preferably has a sleep disturbance; in either cases by means of one or more high-concentration capsaicin and / or capsaicinoid topical dose units, preferably pharmaceutical patches, comprising capsaicin and / or capsaicinoid at a concentration of at least 2.5 wt.-%, relative to the total weight of dose unit.

The present invention relates to a topical pharmaceutical composition of tyrosine kinase inhibitors for the prevention or treatment of posterior eye disease. The topical pharmaceutical composition of the present invention is useful to deliver a high concentration of an active pharmaceutical ingredient such as tyrosine kinase inhibitor in the posterior segment of the eye for example at a concentration of up to 10000 times higher than the IC50 value of the active pharmaceutical ingredient.

To provide a PARP1 inhibitor and its use.SOLUTION: PARP1 inhibitors and pharmaceutical compositions comprising such inhibitors are described herein. The subject compounds and compositions are useful for the treatment of cancer. The compounds described herein are administered to a subject in need thereof according to standard pharmaceutical practice, either alone or in combination with pharmaceutically acceptable carriers, excipients or diluents, in a pharmaceutical composition. In one embodiment, the compounds of the invention can be administered to an animal. The compounds can be administered orally or parenterally, including the intravenous, intramuscular, intraperitoneal, subcutaneous, rectal and topical routes of administration.SELECTED DRAWING: None

A method of enhancing the quality of a skin scar by topical application of an agent for improving scar quality is characterised in that said agent is pre-emptively applied to a potential surgical cutaneous site in advance of surgery, including surgery involving use of lasers. The topical agent may be a polyphenol, such as (-)-epigallocatechin-3-gallate (EGCG). Use of such a topical agent in advance of surgery leads to significant beneficial effects on dermal scarring by reducing mast cells, angiogenesis, skin thickness and simultaneously increasing elastin content. The topical agent may be applied directly or incorporated in a dressing, such as in a dermal patch comprising an adhesive silicone sheet, and can be worn both in the lead up to surgery and post-operatively.

Dermatological treatments and systems employing cooling, topicals, and / or abrasion are disclosed herein. The system can include a cold plate and a suspension assembly tip. The suspension assembly tip can be selectively coupleable to the cold plate. The suspension assembly tip can include a suspension tip and a suspension. The suspension tip can include a contact surface that can be contacted onto a patient's skin to provide a treatment. The suspension can couple to both the cold plate and to the suspension tip. The suspension can be thermally conductive so as to closely thermally couple the suspension tip to the cold plate, or the suspension tip can have a low thermal conductivity so as to not closely thermally coupled the suspension tip to the cold plate.

A skin treatment device is provided with a thermally modulated treatment head adapted for contact with a user or other subject's skin. The device includes one or more thermal elements adapted to modulate the temperature of the head, a power source adapted to provide current to the thermal elements, and a controller adapted to modulate the head temperature by controlling the current delivered to the thermal elements. A topical agent can be disposed between the treatment head and the subject's skin, where the temperature of the topical agent is modulated in response to the temperature thereof.

This product is a skin care glove made of a sheet of laminated nonwoven fabric and microfiber or nanofiber, and is formed by fusing the peripheral edges except for the wrist opening. The product is formed from a thin sheet that is translucent, and when worn on a hand that has been treated with a skin topical agent such as lotion, emulsion, or cream, it adheres closely to the skin, improving the fit and creating a transparent texture, as shown in the "Reference Photo Showing the Condition of Use." The product can be worn on either the left or right hand.

To develop a novel method for treatment of diseases leading to serious corneal and conjunctival epithelial damage resulting from functional impairment of corneal and conjunctival epithelial stem cells, including severe ocular surface disease attributable to chronic graft-versus-host disease.SOLUTION: The present invention provides a prophylactic or treatment agent for severe ocular surface disease for topical administration, comprising apocynin as an active ingredient.SELECTED DRAWING: None

and salts thereof, and contains, as a solvent, any of the solvents indicated by solvents (a)-(g). Solvent (a): dibasic acid diester; solvent (b): lower alcohol and dibasic acid diester; solvent (c): lower alcohol and dimethyl sulfoxide; solvent (d): dimethyl sulfoxide and dibasic acid diester; solvent (e): lower alcohol, dimethyl sulfoxide, and dibasic acid diester; solvent (f): lower alcohol and glycol; and solvent (g): lower alcohol, glycol, and dibasic acid diester.

The purpose of the present invention is to develop a novel treatment method for diseases such as severe ocular surface diseases caused by chronic graft-versus-host disease, which cause severe corneal and conjunctival epithelial damage due to dysfunction of corneal and conjunctival epithelial stem cells. SOLUTION: The present invention provides a topically administered agent for preventing or treating severe ocular surface diseases, which contains apocynin as an active ingredient.

The invention discloses an emulsion type suppository practical for vaginal administration, and relates to the technical field of pharmaceutical preparations, the suppository is a solid at room temperature, and can be converted into a cream type preparation in situ under vaginal temperature and wetting conditions; the suppository is composed of active and pharmaceutically acceptable auxiliary materials, the auxiliary materials comprise structural lipid, an emulsifier, a gel matrix and a pH regulator, and a suppository body is softened at body temperature and mixed with body fluid to form a cream mixture easy to coat on the mucous membrane surface in situ. The transformation process avoids greasy feeling and local discomfort possibly brought by a traditional greasy suppository, and also eliminates the trouble that the prefabricated cream needs to be matched with a special administration device, so that the local medication experience of a patient is improved while the administration convenience is ensured. Besides, through reasonable selection of auxiliary materials, the cream formed through conversion can provide proper adhesion, and the retention time of the medicine at the action part can be prolonged.

Provided are a usage method for a topical agent composition and a topical agent composition that make it possible for an oil-soluble component of the topical agent composition to achieve effective penetration. According to the present invention, a usage method for a topical agent composition involves applying a topical agent composition that includes water and solubilized micelles that encapsulate an oil-soluble component in a surfactant to a body surface, applying energy to the body surface to which the topical agent composition has been applied from above the topical agent composition using a beauty apparatus, and allowing the solubilized micelles to penetrate in from the body surface.

This invention relates to a topical agent for preventing and treating poplar canker and its application method. The topical agent, by weight percentage, comprises the following ingredients: 0.1-0.2% pyraclostrobin; 1-3% wetting and dispersing agent; 0.2%-0.8% thickener; 2-4% antifreeze agent; 0.01%-0.3% micronutrient fertilizer; 0.1%-0.3% defoamer; and the balance being deionized water. Before application, first use a scraper to clean the ulcerated areas on the poplar branches and trunks, thoroughly scraping away the rotten tissue, extending 2-3 cm beyond the diseased area on both the upper and lower surfaces. Then, evenly and promptly apply the topical agent to the treated wound surface, cover it with breathable non-woven fabric, and then apply another layer of topical agent over the non-woven fabric, ensuring close adhesion to the branches and trunk. The topical agent of this invention is simple to use, highly effective, and can effectively control canker, reduce the impact on poplar growth, and achieve efficient prevention and treatment of poplar canker.

The present invention relates to topical pharmaceutical compositions comprising a corticosteroid and an insecticide selected from pyrethrin or a synthetic pyrethroid insecticide. Methods for their use in the treatment of allergic dermatitis, particularly hypersensitivity to insect bites, in animals using the compositions of the invention are also described.

A composition for treating astrophic vaginitis including a cream base including sildenafil citrate and oxytocin. The composition of claim 1, wherein the sildenafil citrate is in a dosage in the range of 25 mg / dose to 100 mg / dose, and oxytocin is in a dosage in the range of 40 IU / dose to 400 IU / dose. In another aspect, the composition further includes a buffering agent. In a further aspect, the buffering agent is L-arginine. In a further aspect, the buffering agent is sodium phosphate monobasic.

The present invention provides compositions and methods for orally and / or topically treating skin diseases and conditions, such as acne, atopic dermatitis, psoriasis, facial redness, folliculitis, dry skin, itchy skin, hyperpigmentation, aging, wrinkles, etc., by administering to a subject in need thereof a pharmaceutical composition or dietary supplement comprising an in vitro grown grape cell line culture. Additionally, the present invention provides methods and compositions for treating skin conditions and diseases, such as acne, atopic dermatitis, psoriasis, facial redness, folliculitis, dry skin, itchy skin, aging, wrinkles, etc., by topically administering to a subject in need thereof a pharmaceutical composition or cosmetic composition comprising an in vitro grown grape cell line culture.

A method for treating an allergy condition of an animal includes detecting that the animal has one or more allergy condition, where the one or more allergy condition comprises one or more plant-based allergen, one or more mold or fungus-based allergen, one or more mite or insect-based allergen, or a combination thereof. The method includes determining a first quantity of a topical application medium and a first quantity of the one or more allergens based at least in part on one or more attributes of the animal. The method includes providing a first topical application compound, the first topical application compound comprising the first quantity of the one or more allergens and the first quantity of the topical application medium. The method includes applying the first topical application compound to the animal to treat the allergy condition.

The invention is implemented into the category of transdermal topical agents for use in regulating the dilation of blood vessels. The IP-6, Inositol, and colloidal oatmeal Nerve Relaxing Transdermal Topical Cream, Gel, or Ointment for Raynaud's Syndrome is the first topical cream containing any or all of the following: IP-6, inositol, and colloidal oatmeal, with IP-6 as the carrier agent. The present invention will allow for the decrease in the time to full clinical effect, eliminate having to wear a patch of paper over the application site, and eliminate the problem of skin irritation due to the IP-6 delivering the colloidal oatmeal to the application area to provide extra soothing and moisturizing properties. The present invention is specifically and uniquely designed for ease of use and quick action of full clinical effect with the relaxation of nerve endings that lead to dilation of extremely constricted blood vessels in mind.

This invention discloses a traditional Chinese medicine composition for the prevention and treatment of throat and oral diseases, and its preparation method. The composition comprises poultry egg yolk oil, honey, platycodon root, dandelion, licorice, monk fruit, menthol, and maltose in specific weight proportions. Its preparation includes steps such as frying poultry egg yolk oil, preparing water extracts of platycodon root and dandelion, and mixing with maltose to form a final product. The composition of this invention uses only food-grade medicinal materials, ensuring safety and reliability. When formulated into topical dosage forms such as lozenges, it provides long-lasting effects on the affected area, offering multiple benefits including analgesia, anti-inflammation, mucosal repair, and cough suppression. It effectively solves the problems of significant side effects and limited duration of local application in existing oral medications. This product has a pleasant taste and high patient compliance, making it suitable for the prevention and treatment of throat and oral diseases such as pharyngitis, tonsillitis, oral ulcers, gingivitis, and sore throat.

Dermatological treatments and systems employing cooling, topicals, and / or abrasion are disclosed herein. The system can include a cold plate and a suspension assembly tip. The suspension assembly tip can be selectively coupleable to the cold plate. The suspension assembly tip can include a suspension tip and a suspension. The suspension tip can include a contact surface that can be contacted onto a patient's skin to provide a treatment. The suspension can couple to both the cold plate and to the suspension tip. The suspension can be thermally conductive so as to closely thermally couple the suspension tip to the cold plate, or the suspension tip can have a low thermal conductivity so as to not closely thermally coupled the suspension tip to the cold plate.

A new means of intradermal delivery of a useful component is provided. Disclosed are an external-use skin preparation composition comprising fine needlelike taurine crystals including a useful component in the crystals, and a method for producing a fine needlelike taurine crystal including a useful component in the crystal, the method comprising a step of growing a crystal in an environment in which an aqueous solution (A) containing taurine dissolved is mixed with or held in contact with a liquid substance (B) having low solubility of taurine, wherein the useful component is dissolved or dispersed in the aqueous solution (A) or the liquid substance (B), whereby the useful component is included in the crystal along with the growth of the crystal.

Treatment compositions and methods for treating and / or preventing actinic keratosis comprising applying a chlorin treatment composition in a topical form to one or more actinic keratosis lesions. A treatment composition preferably comprises a copper chlorin, such as a sodium copper chlorophyllin complex, trisodium copper chlorin p6, disodium copper isochlorin e4, or trisodium copper chlorin e6. A treatment composition comprises around 0.002% to around 0.1% by weight of copper chlorin. Treatments disclosed herein may result in elimination of the actinic keratosis lesions.

In one aspect, the disclosure relates to clearing compounds capable of rendering at least one tissue transparent for a period of time, compositions comprising the same, pendant molecules bonded to the compounds capable of covalently or non-covalently binding to tissue such as collagen mimetic peptide, and macromolecules derivatized with the same. In another aspect, the compositions can be useful in clinic for visualizing internal anatomical structures and / or for clearing opacities of the eye. In one aspect, the compositions are topical, e.g., eye drops, lotions, or creams, or are injectable. In some aspects, an injection is performed directly into opaque tissue such as neural tissue, connective tissue, internal organs, ocular tissue, or the like. In other aspects, the clearing compound is injected adjacent to the target structure. The clearing compounds can be colorless across the entire visible spectrum, are non-toxic, and are excreted by the subject after visualization of tissue structures.

This invention provides compositions and methods of treating subjects with wounds. Compositions include dressings comprising a sheet and an adhesive, wherein the adhesive is adhered to the sheet, and wherein the sheet has channels. In some embodiments, the channels comprise two different classes of channels (e.g. liquid channels and air channels). These dressing can be applied to various kinds of skin injuries and remain affixed, protecting the injury from contaminants and at the same time, allowing exchange of exudates on the proximal (injury) side to the distal side and exchange of topical agents applied from the distal side of the dressing to the wound while also allowing exchange of gasses from the injury to the air and air to the wound.

The present invention relates to compositions, systems, and methods for treating a subject with an eye condition (e.g., topically) using a composition comprising an ACE-2 receptor antagonist (also known as Angiotensin II Receptor Blocker or “ARB”) (e.g., losartan, telmisartan, valsartan, olmesartan, candesartan, irbesartan, eprosartan, azilsartan, or losartan metabolite EXP3174). In certain embodiments, the eye condition is selected from: i) a corneal scarring fibrosis, ii) a transforming growth factor beta-induced (TGFBI) corneal dystrophy, iii) a conjunctival fibrotic disease, iv) an intraocular fibrotic disease, and v) a conjunctival bleb scarring and / or shunt encapsulation (e.g., following glaucoma surgery).

The present disclosure relates to a nicotinic acid riboside derivative compound or a nicotinamide riboside derivative compound. The derivative compound has excellent heat stability and efficiently induces the biosynthesis of nicotinamide adenine dinucleotide (NAD+). The derivative compound, a physiologically acceptable salt thereof and / or a stereoisomer thereof may be utilized as an effective ingredient or an active ingredient of an anti-inflammatory composition, a composition for alleviating or improving inflammation, an anti-aging composition and / or an anti-aging dermatological topical agent.

Embodiments disclosed provide pharmaceutical formulations for tyrosinase inhibitors, as well as methods for dermatological treatment of hyperpigmentation disorders. The pharmaceutical formulations comprise tyrosinase inhibitors, each containing a structural core of 8-hydroxyquinoline, and are applied in a suitable carrier as topical treatments for hyperpigmentation. In some embodiments at least one additional dermatologically active compound is present in the pharmaceutical formulation.

Provided is a topical composition for treating a skin condition such as acne vulgaris in a subject in need thereof. In particular, the topical composition comprises 2% salicylic acid as an active agent; 15% dimethyl sulfoxide operating as a tissue penetrating solvent; 85% dipropylene glycol as a tissue penetrating diluent; oleic acid as a tissue penetrating agent; and a stabilizer comprising 1% ascorbic acid for maintaining the composition, which also functions to maintain chemical stability and resistance to degradation.